Data has shown the effectiveness of factor XI in postoperative venous thromboembolism (VTE) is still unknown, particularly when compared to preoperative inhibition. A recent phase 2 study compared the efficacy and safety of abelcaimab administered postoperative in comparison to the efficacy and safety of enoxaparin in patients undergoing total knee arthroplasty.

A single IV dose of the factor XI monoclonal antibody abelacimab appeared superior to daily enoxaparin for preventing venous thromboembolism after total knee arthroplasty, according to randomized study results. The results — presented at International Society on Thrombosis and Hemostasis Congress and published in The New England Journal of Medicine — showed abelacimab (Anthos Therapeutics) reduced blood […]

July 19 (UPI) — The drug abelacimab prevents blood clots in patients undergoing knee replacement surgery, a study published by the New England Journal of Medicine found. Abelacimab, developed by Cambridge, Mass.-based Anthos Therapeutics, reduced the risk for blood clots in people who had the procedure by about 80% compared with the blood-thinner enoxaparin, the data showed.